Treatment of disseminated renal cancer: systemic immunotherapy, palliative treatment

Česká verzia

Authors: J. Katolická
Authors place of work: Onkologicko-chirurgické oddělení FN u svaté Anny v Brně
Published in the journal: Urol List 2012; 10(2): 40-42

Summary

Both chemotherapy and radiotherapy do not significantly improve treatment response or overall survival in patients with metastatic renal cancer. Interferon alpha proved to be effective in the treatment of disseminated renal cancer. Interleukin-2 can be applied either subcutaneously or intravenously. Combination of both cytokines has not shown survival improvement. Combination of interferon alpha and bevacizumab is indicated for treatment of metastatic renal cancer in patients with good prognosis.

Key words:
metastatic renal cancer, interferon alpha, interleukin 2, bevacizumab

Zdroje

1. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20(2): 303–321.

2. Bleumer I, Oosterwijk E, De Mulder P et al. Immunotherapy for renal cell carcinoma. Eur Urol 2003; 44: 65–75.

3. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma (AVOREN): final analysis of overal survival. J Clin Oncol 2010; 282: 144–150.

4. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353(9146): 14–17.

5. Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal call carcinoma. J Clin Oncol 2000; 18(16): 2972–2980.

6. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d´Immunothérapie. N Engl J Med 1998; 338(18): 1272–1278.

7. Atzpodien J, Kirchner H, Illiger HJ et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-termn results of a controlled randomized clinical trial. Br J Cancer 2001; 85(8): 1130–1136.

8. VaHerpen CM, Jansen RL, Kruit WH et al. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 2000; 82(4): 772–776.

9. Negrier S, Caty A, Lesimple T et al. Treatment of patients with metastatic renal carcinoma with combination of subcutaneous interleukin-2 an interferon alfa with or without fluorouracil. Groupe Francais d’Immunothérapie, Fédération Nationale des Cencters de Lutte Contre le Cancer. J Clin Oncol 2000; 18(24): 4009–4015.

10. Petruželka L, Babjuk M et al. Léčba metastatických nádorů ledvin. Praha: Galén 2011.